Audio roundup of selected biopharma industry content from Scrip over the business week ended June 5, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time – Revolution’s daraxonrasib makes splash at ASCO; Merck &amp; Co. lays out oncology vision; US legislators bristle over US-China deals; obesity challengers at ADA; and big pharma CEO pay rebounds in 2025. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-UH6HET2LLNGUJBCSJ3UA2KLGCQ/

Scrip's Five Must-Know Things - June 8, 2026

Citeline Podcasts

[SPEAKER_A] Hello and welcome to the podcast edition of Scrip's Five Must-Know Things, this time for the business week ended June 5, 2026. This is Ian Haydock. This episode was produced with the help of AI-powered text-to-voice and voice emulation tools. This time: Revolution's daraxonrasib makes splash at ASCO; Merck Co. lays out oncology vision; US legislators bristle over US-China deals; obesity challengers at ADA; and big pharma CEOs pay rebounds in 2025. Not just a home run, but a grand slam. That's how American Society of Clinical Oncology Chief Medical Officer Julie Gralow Scrip described results from the Phase 3 RASOLOOT-302 trial of Revolution Medicine's daraxonrasib in previously treated metastatic pancreatic adenocarcinoma during a press briefing at the 2026 ASCO meeting, Alaric de Armond writes. The US biotech presented data from the 500-patient study of its RAS/ONT inhibitor during the meeting in Chicago, and the company told Scrip it is actively preparing global regulatory submissions, including in the US, which will incorporate the new data. During the May 30 press briefing, presenter Brian Wolpin, director of the Gastrointestinal Cancer Center at the Dana-Farber Cancer Institute, highlighted the inadequacy of current chemotherapy options for pancreatic cancer, where RAS signaling is an important driver of tumor growth. More than 90% of PDAC tumors harbor an oncogenic RAS mutation, but there have been no approved therapies that target RAS that can be used for pancreatic cancer. In the RASALUTE trial, RAS G12 mutation-positive population, median overall survival was 13.2 months for patients receiving daraxonrasib versus 6.6 months for patients in the control arm, which received investigator's choice of chemotherapy. Median OS was similar in the overall population, —with a 13.2-month OS for patients in the daraxonrasib arm and 6.7 months in the control arm.

Scrip's Five Must-Know Things - June 8, 2026

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Scrip's Five Must-Know Things - June 8, 2026

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.